LINC02345: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC02345

NCBI ID: G101928227

LINC02345

Other Name(s): long intergenic non-protein coding RNA 2345 | Long intergenic non-protein coding RNA 2345

LINC02345: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC02345 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as a potential drug target and biomarker. It is a non-coding RNA molecule that is expressed in various tissues and cell types in the human body. LINC02345 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival.

The discovery and characterization of LINC02345

LINC02345 was first identified using transcriptomics techniques as a differentially expressed gene in various tissues and cell types. The gene was found to be located in the X chromosome and encode a non-coding RNA molecule. The RNA molecule was shown to have a partial melting structure, with a clear intron-exon boundary and a single exon.

Subsequent studies have characterized the LINC02345 protein and its function in various cell types. It has been shown to play a role in the regulation of cell proliferation, differentiation, and survival. LINC02345 has also been shown to interact with several protein molecules, including the transcription factor, p53.

The potential implications of LINC02345 as a drug target

The potential implications of LINC02345 as a drug target are vast and varied. One potential mechanism by which LINC02345 could be targeted is through its role in cell proliferation and survival. LINC02345 has been shown to play a role in the regulation of cell growth and differentiation, and it is possible that targeting LINC02345 could lead to the inhibition of cell proliferation and survival.

Another potential mechanism by which LINC02345 could be targeted is through its role in the regulation of gene expression. LINC02345 has been shown to interact with several protein molecules, including the transcription factor, p53. This suggests that LINC02345 may play a role in the regulation of gene expression and that targeting LINC02345 could lead to the inhibition of gene expression.

The potential implications of LINC02345 as a biomarker

The potential implications of LINC02345 as a biomarker are also vast and varied. One potential use of LINC02345 as a biomarker is in the diagnosis of cancer. LINC02345 has been shown to play a role in the regulation of cell proliferation and survival, and it is possible that targeting LINC02345 in cancer cells could lead to the inhibition of cell proliferation and survival.

Another potential use of LINC02345 as a biomarker is in the monitoring of disease progression. LINC02345 has been shown to play a role in the regulation of cell survival and proliferation, and it is possible that targeting LINC02345 in disease-related samples could lead to the inhibition of cell survival and proliferation.

Conclusion

In conclusion, LINC02345 is a long intergenic non-protein-coding RNA that has been identified as a potential drug target and biomarker. Its function in the regulation of cell proliferation, differentiation, and survival makes it a promising target for drug development. Further studies are needed to fully understand the role of LINC02345 in various cell types and to determine its potential as a biomarker for disease diagnosis and progression.

Protein Name: Long Intergenic Non-protein Coding RNA 2345

The "LINC02345 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02345 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets